Skip to main content

pralatrexate

Generic: PRALATREXATE·Brand: FOLOTYN, PRALATREXATE

pralatrexate: 3 clinical trials tracked.

pralatrexate evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pralatrexate, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trial Registry Records (3)

Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma

NCT07691450Registry updated 2026-07-09·Phase 1
Not yet recruiting

Primary endpoint: Occurrence of dose-limiting toxicities (DLT) (Arm A)

Interventionalopen40 targetStarted 2027-01Completion 2029-111 site · United StatesCity of Hope Medical Center

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048Registry updated 2026-09-25·Phase 3·CRVS
Recruiting

Primary endpoint: Progression-free survival

InterventionalRandomizedopen150 targetStarted 2024-10Completion 2028-1237 sites · Australia, Canada, United StatesCorvus Pharmaceuticals, Inc.

A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998Registry updated 2026-05-26·Phase 1/Phase 2
Active, not recruiting

Primary endpoint: Number of Participants Who Had Dose Limiting Toxicities

Interventionalopen13 targetStarted 2019-02Completion 2027-023 sites · United StatesCity of Hope Medical Center